Skip to main content
. 2016 May 30;7(29):46653–46661. doi: 10.18632/oncotarget.9695

Figure 1.

Figure 1

A. Correlation between distant metastasis-free survival (DMFS) for patients and CD4/CD8 ratio showing that patients with a higher CD4/CD8 ratio (≥ 1.77) have a better 5-year DMFS compared to those with a lower ratio (91.9% vs. 85.4%, P < 0.001). B. DMFS for patients with early N stage vs. advanced N stage showing that patients with advanced N stage (N2-3) display poorer 5-year DMFS compared with patients with early N stage 0-1 (93.2% vs. 83.1%, P = 0.001).